Article by Bruce Sylvester. Lisdexamfetamine treatment could be therapeutic for adults with attention-deficit/hyperactivity disorder (ADHD) who also have sluggish cognitive tempo (SCT). The findings were published on June… read more.
Supernus Pharmaceuticals announced that the FDA approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age…. read more.
KemPharm, Inc. has announced that the FDA has approved the New Drug Application for Azstarys (formerly referred to as KP 415), a once-daily product for the treatment of… read more.
Attention Deficit Hyperactive Disorder (ADHD) can have negative consequences on mental health into adulthood.
Low levels of key, body-regulating chemicals in mothers during the first three months of pregnancy may interfere with the baby’s brain development, a large American study shows.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
